title: [Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer].
abstract: Herein, we describe hepatic arterial infusion (HAI) chemotherapy with gemcitabine (GEM) for the treatment of patients with postoperative liver metastases from pancreatic cancer. Seven patients received HAI with GEM plus 5-fluorouracil (5- FU) or oral S-1 from 2008 to 2010 at the Kanazawa University Hospital. Of the 7 patients, partial response (PR) and stable disease( SD) were observed in 6 patients according to the Response Evaluation Criteria In Solid Tumors( RECIST) evaluation criteria (response rate, 85.7%). The median survival time was 14 months; however, all 7 patients ultimately died of another metastatic lesion. Importantly, there were no life-threatening toxicities. However, 6 patients developed catheter- related complications, and the HAI catheter and the subcutaneous implantable port system had to be removed. Peripheral blood concentrations of GEM after HAI were analyzed in 7 other patients. At a dose level of 400 to 800 mg/standard liver volume( SLV),the GEM concentrations were less than one-tenth that of the intravenously administered 1,000 mg/m2. However, at a dose level of 1,000 mg/SLV, the GEM concentration in the peripheral blood was almost the same as that administered intravenously. In conclusion, HAI chemotherapy is safe and effective for the treatment of patients with liver metastases from pancreatic cancer. Our results suggest that a dose level of 800 mg/SLV could be considered optimal for local therapy.
authors.affiliation: Dept. of Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University.
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Tajima
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Kitagawa
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Shoji
authors.forename: Koichi
authors.initials: K
authors.lastname: Okamoto
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nakanuma
authors.forename: Seisho
authors.initials: S
authors.lastname: Sakai
authors.forename: Jun
authors.initials: J
authors.lastname: Kinoshita
authors.forename: Isamu
authors.initials: I
authors.lastname: Makino
authors.forename: Hironori
authors.initials: H
authors.lastname: Hayashi
authors.forename: Keishi
authors.initials: K
authors.lastname: Nakamura
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Oyama
authors.forename: Hisatoshi
authors.initials: H
authors.lastname: Nakagawara
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Miyashita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takamura
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Ohta
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Minami
authors.forename: Wataru
authors.initials: W
authors.lastname: Koda
authors.forename: Junichiro
authors.initials: J
authors.lastname: Sanada
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Gabata
authors.forename: Yoshimichi
authors.initials: Y
authors.lastname: Sai
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000093542:Gemcitabine